These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 28746871)

  • 1. The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy.
    Zingg D; Arenas-Ramirez N; Sahin D; Rosalia RA; Antunes AT; Haeusel J; Sommer L; Boyman O
    Cell Rep; 2017 Jul; 20(4):854-867. PubMed ID: 28746871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EZH2 Cooperates with DNA Methylation to Downregulate Key Tumor Suppressors and IFN Gene Signatures in Melanoma.
    Tiffen J; Gallagher SJ; Filipp F; Gunatilake D; Emran AA; Cullinane C; Dutton-Register K; Aoude L; Hayward N; Chatterjee A; Rodger EJ; Eccles MR; Hersey P
    J Invest Dermatol; 2020 Dec; 140(12):2442-2454.e5. PubMed ID: 32360600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effects and molecular mechanism of histone methyltransferase enhancer of zeste homolog 2 on regulating sepsis-induced T cell dysfunction].
    Li Z; Zhao D; Zhou X; Tang L
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2022 Apr; 34(4):357-361. PubMed ID: 35692198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma.
    Xiao G; Jin LL; Liu CQ; Wang YC; Meng YM; Zhou ZG; Chen J; Yu XJ; Zhang YJ; Xu J; Zheng L
    J Immunother Cancer; 2019 Nov; 7(1):300. PubMed ID: 31727135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy.
    Goswami S; Apostolou I; Zhang J; Skepner J; Anandhan S; Zhang X; Xiong L; Trojer P; Aparicio A; Subudhi SK; Allison JP; Zhao H; Sharma P
    J Clin Invest; 2018 Aug; 128(9):3813-3818. PubMed ID: 29905573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic mechanisms of tumor resistance to immunotherapy.
    Arenas-Ramirez N; Sahin D; Boyman O
    Cell Mol Life Sci; 2018 Nov; 75(22):4163-4176. PubMed ID: 30140960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stat3-mediated Atg7 expression regulates anti-tumor immunity in mouse melanoma.
    Zimmerman SM; Suh E; Smith SR; Souroullas GP
    Cancer Immunol Immunother; 2024 Sep; 73(11):218. PubMed ID: 39235510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting EZH2 Enhances Antigen Presentation, Antitumor Immunity, and Circumvents Anti-PD-1 Resistance in Head and Neck Cancer.
    Zhou L; Mudianto T; Ma X; Riley R; Uppaluri R
    Clin Cancer Res; 2020 Jan; 26(1):290-300. PubMed ID: 31562203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.
    Wei SC; Levine JH; Cogdill AP; Zhao Y; Anang NAS; Andrews MC; Sharma P; Wang J; Wargo JA; Pe'er D; Allison JP
    Cell; 2017 Sep; 170(6):1120-1133.e17. PubMed ID: 28803728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Energy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint blockade.
    Dai X; Bu X; Gao Y; Guo J; Hu J; Jiang C; Zhang Z; Xu K; Duan J; He S; Zhang J; Wan L; Liu T; Zhou X; Hung MC; Freeman GJ; Wei W
    Mol Cell; 2021 Jun; 81(11):2317-2331.e6. PubMed ID: 33909988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of EZH2 methyltransferase decreases immunoediting of mesothelioma cells by autologous macrophages through a PD-1-dependent mechanism.
    Hamaidia M; Gazon H; Hoyos C; Hoffmann GB; Louis R; Duysinx B; Willems L
    JCI Insight; 2019 Sep; 4(18):. PubMed ID: 31534051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EZH2 Inhibitor Enhances the STING Agonist‒Induced Antitumor Immunity in Melanoma.
    Xu T; Dai J; Tang L; Yang L; Si L; Sheng X; Cui C; Chi Z; Kong Y; Guo J
    J Invest Dermatol; 2022 Apr; 142(4):1158-1170.e8. PubMed ID: 34571002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity.
    Wang D; Quiros J; Mahuron K; Pai CC; Ranzani V; Young A; Silveria S; Harwin T; Abnousian A; Pagani M; Rosenblum MD; Van Gool F; Fong L; Bluestone JA; DuPage M
    Cell Rep; 2018 Jun; 23(11):3262-3274. PubMed ID: 29898397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Favorable alteration of tumor microenvironment by immunomodulatory cytokines for efficient T-cell therapy in solid tumors.
    Tähtinen S; Kaikkonen S; Merisalo-Soikkeli M; Grönberg-Vähä-Koskela S; Kanerva A; Parviainen S; Vähä-Koskela M; Hemminki A
    PLoS One; 2015; 10(6):e0131242. PubMed ID: 26107883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses.
    Chen X; Pan X; Zhang W; Guo H; Cheng S; He Q; Yang B; Ding L
    Acta Pharm Sin B; 2020 May; 10(5):723-733. PubMed ID: 32528824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EZH2, a prominent orchestrator of genetic and epigenetic regulation of solid tumor microenvironment and immunotherapy.
    Sun S; Yu F; Xu D; Zheng H; Li M
    Biochim Biophys Acta Rev Cancer; 2022 Mar; 1877(2):188700. PubMed ID: 35217116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2.
    Christofides A; Karantanos T; Bardhan K; Boussiotis VA
    Oncotarget; 2016 Dec; 7(51):85624-85640. PubMed ID: 27793053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.
    Hannani D; Vétizou M; Enot D; Rusakiewicz S; Chaput N; Klatzmann D; Desbois M; Jacquelot N; Vimond N; Chouaib S; Mateus C; Allison JP; Ribas A; Wolchok JD; Yuan J; Wong P; Postow M; Mackiewicz A; Mackiewicz J; Schadendorff D; Jaeger D; Zörnig I; Hassel J; Korman AJ; Bahjat K; Maio M; Calabro L; Teng MW; Smyth MJ; Eggermont A; Robert C; Kroemer G; Zitvogel L
    Cell Res; 2015 Feb; 25(2):208-24. PubMed ID: 25582080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polycomb repressor complex 2 suppresses interferon-responsive MHC-II expression in melanoma cells and is associated with anti-PD-1 resistance.
    James JL; Taylor BC; Axelrod ML; Sun X; Guerin LN; Gonzalez-Ericsson PI; Wang Y; Sanchez V; Fahey CC; Sanders ME; Xu Y; Hodges E; Johnson DB; Balko JM
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38315170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective induction of melanoma-antigen-specific CD8+ T cells via Vγ9γδT cell expansion by CD56(high+) Interferon-α-induced dendritic cells.
    Nieda M; Terunuma H; Eiraku Y; Deng X; Nicol AJ
    Exp Dermatol; 2015 Jan; 24(1):35-41. PubMed ID: 25363560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.